Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant

Inclusion Criteria: * Patients undergoing allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia (CML) in accelerated or blast phase, acute myeloid leukemia (AML) beyond first remission, primary refractory AML, therapy-related AML at any stage, or acute leukemia at any stage arising in a patient with an antecedent diagnosis of a myelodysplastic or myeloproliferative syndrome (including chronic myelomonocytic leukemia, CML, polycythemia vera, essential thrombocytosis, and agnogenic myeloid metaplasia with myelofibrosis) * Patients and donors must both be human leukocyte antigen (HLA)-A2 positive * Patients must be able to provide blood and bone marrow samples required for this protocol * Eligibility for Prophylactic Treatment with CD8+ CTL After Transplant (Highest Risk Subgroup): * At time of planned treatment, CD8+ CTL specific for PR3 must have been generated and have completed Quality Control (QC) testing * Patients must have had \> 5% morphologic blasts detectable in bone marrow or peripheral blood just prior to or at the time of transplant * Patients must have evidence of posttransplant recovery of normal hematopoiesis (absolute neutrophil count \[ANC\] \> 500/mm\^3) for at least 7 days prior to the initiation of CTL infusions * Patients on immunosuppressive therapy for graft-versus-host disease (GVHD) are eligible for treatment if not receiving corticosteroids or if the dose of corticosteroids can be tapered to \< the equivalent of 0.5 mg/k…